SCHEDULE: Bain Capital Life Sciences Discloses 5.1% Stake in Pharvaris N.V.

Bain Capital Life Sciences entities have disclosed a collective beneficial ownership of 5.1% in Pharvaris N.V., totaling 3,181,275 ordinary shares as of September 30, 2025.

Summary

• Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP, and Bain Capital Life Sciences Opportunities III, LP (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G.
• As of September 30, 2025, the Reporting Persons collectively beneficially own 3,181,275 Ordinary Shares of Pharvaris N.V.
• This aggregate ownership represents approximately 5.1% of the outstanding Ordinary Shares of Pharvaris N.V.
• The percentage is based on 62,743,142 Ordinary Shares outstanding as of July 22, 2025, as reported by the Issuer.
• The investment is passive, with the Reporting Persons certifying that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable life sciences investment firm like Bain Capital is generally viewed positively, indicating investor confidence in the company. However, it's a factual disclosure, not a performance report, so the sentiment is moderately positive rather than strongly so.

Positives

• A significant institutional investor, Bain Capital Life Sciences, has taken or maintained a substantial stake in Pharvaris N.V., indicating confidence in the company's long-term prospects.
• The investment is passive, suggesting a belief in the current management and strategic direction without immediate intent to influence control.

Risks

• The filing itself does not detail specific risks related to Pharvaris N.V.'s operations or financial health, as it is a disclosure of beneficial ownership.

Future Outlook

N/A. This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future outlook.

Industry Context

N/A. This filing is a disclosure of beneficial ownership and does not provide analysis of broader industry trends or competitors.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a passive stake can instill confidence and potentially stabilize the stock price. It signals external validation of the company's value.

Key Dates

Recommendation

The filing indicates a significant, passive investment by Bain Capital Life Sciences in Pharvaris N.V., suggesting confidence in the company's long-term prospects without an immediate intent to influence control. While this is a positive signal, the filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a substantial institutional stake, which supports a 'hold' position for existing investors and suggests potential stability for new investors to consider further due diligence.

Keywords

Pharvaris N.V., Bain Capital Life Sciences, Schedule 13G, Beneficial Ownership, Institutional Investment, Ordinary Shares, Biotechnology, Life Sciences